When Interests Align: Medication Adherence
This article was originally published in RPM Report
When you think about the impact of the Food & Drug Administration’s focus on real-world drug safety, the disruptive implications of the Affordable Care Act, and the relentless pressure to find savings in health care, it is easy to see the dangers posed to biopharma companies. But those forces aren’t all negative. In fact, they are helping to mobilize government, consumer groups and payors to push hard on at least one decidedly pro-pharma agenda: improving adherence with prescription medicines.
You may also be interested in...
In recent years, it has become standard practice for marketers of pharmaceutical and biotechnology products to offer a whole host of wraparound services to bolster the value proposition of their brands. Why not sell them?
Capgemini’s calculations of potential pharmaceutical revenues if patients were fully compliant with their drug therapy regimens suggest revenues in the U.S. would be nearly 60% higher. But even small changes have sizeable revenue impact.
The online service is aimed at helping patients understand their disease states and properly administering self-injected drugs. Pharmaceutical manufacturers could help develop content.